Agios Pharmaceuticals, Inc. (AGIO) vs Braveheart Bio, Inc. (BRVE)

Agios Pharmaceuticals, Inc. and Braveheart Bio, Inc. are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Braveheart Bio, Inc. are of similar size ($1.9B and $1.8B). Braveheart Bio, Inc. has the higher net margin (0.00% vs −264.8%) and the higher return on invested capital (−28.7% vs −75.0%). Across the 12 metrics below, Braveheart Bio, Inc. leads on 9 and Agios Pharmaceuticals, Inc. on 3.

Valuation

Metric AGIO BRVE Biotechnology median
P/E n/m n/m 11.36
P/S 13.43 n/m 9.12
P/B 1.93 2.05 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 8.95 n/m 8.56
Earnings yield (19.95%) (61.95%) (34.18%)
Free cash flow yield (17.77%) (4.69%) (23.62%)

Profitability

Metric AGIO BRVE Biotechnology median
Gross margin 93.81% — 67.24%
Operating margin (297.72%) 0.00% 0.00%
Net margin (264.76%) 0.00% 0.00%
Free cash flow margin (238.54%) 0.00% 0.00%
Return on equity (32.95%) 0.00% (50.28%)
Return on assets (30.44%) 0.00% (45.89%)
Return on invested capital (75.02%) (28.66%) 0.00%

Growth

Metric AGIO BRVE Biotechnology median
Revenue growth (TTM) 214.44% — 6.96%
EPS growth (last fiscal year) (161.17%) — 29.86%
Revenue growth, 5-year CAGR (14.45%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AGIO BRVE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.69 21.57 4.72
Net debt to EBITDA 1.80 1.34 1.01

Dividend

Metric AGIO BRVE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AGIO BRVE Biotechnology median
Market cap 1.90b 1.84b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack